UroGen (URGN) Director Receives 20,000 Stock Options, Vesting Over One Year

Rhea-AI Filing Summary

Arie Belldegrun, a director of UroGen Pharma Ltd. (URGN), reported an equity award on 08/26/2025. The Form 4 shows acquisition of 20,000 stock options with an exercise price of $19.50. The options become exercisable on 08/26/2025 and expire on 08/26/2035, and the reporting person beneficially owns 20,000 underlying ordinary shares following the transaction. Per the filing, the shares underlying the option will vest in equal quarterly installments over one year, contingent on the directors continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed via attorney-in-fact on 08/27/2025.

Positive

• Director alignment: Award increases the reporting directors equity stake, aligning interests with shareholders.
• Standard vesting structure: Quarterly vesting over one year provides a clear, short-term retention incentive.
• Clear disclosure: Form 4 details exercise price, exercisable and expiration dates and beneficial ownership post-transaction.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant of 20,000 shares; aligns director with equity ownership but not materially large on its face.

This Form 4 documents a standard equity incentive grant to a board director: 20,000 options exercisable immediately on the grant date with a ten-year term and a $19.50 exercise price. Vesting occurs quarterly over one year, tying continued service to award realization. For investors, such grants are commonly used to align interests of directors with shareholders and conserve cash compensation. The filing alone does not disclose relative dilution or comparative magnitude versus total outstanding shares, so its materiality to URGNs capitalization cannot be assessed from this document alone.

Corporate Governance Expert

TL;DR: Grant follows typical governance practice; quarterly vesting over one year signals short-term retention incentive.

The disclosure shows the award was reported under the companys 2017 Equity Incentive Plan and vests in equal quarterly installments over one year, which is a relatively short vesting horizon for director retention awards. The filing identifies the reporting person as a director and lists ownership as direct. The Form 4 is properly executed by an attorney-in-fact and includes standard grant mechanics (exercise price, exercisable and expiration dates). No amendments, dispositions, or unusual transfer mechanisms are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Belldegrun Arie

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot buy)	$19.5	08/26/2025		A		20,000		(1)	08/26/2035	Ordinary Shares	20,000	$0	20,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

	/s/ Jason D. Smith, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for URGN and what was reported?

The Form 4 was filed for Arie Belldegrun, a director, reporting the acquisition of 20,000 stock options on 08/26/2025.

What are the key terms of the option grant reported on URGN Form 4?

The options have an exercise price of $19.50, become exercisable on 08/26/2025, and expire on 08/26/2035; underlying shares vest quarterly over one year.

How many ordinary shares does the reporting person beneficially own after this transaction?

The filing reports beneficial ownership of 20,000 ordinary shares underlying the option following the reported transaction.

Does the Form 4 show whether the filing was individual or joint?

The Form 4 indicates a single reporting person filed the form (Form filed by One Reporting Person).

Was the Form 4 signed and when was it filed?

The signature on the Form 4 was executed by an attorney-in-fact, Jason D. Smith, dated 08/27/2025.